Clinical Trials Browser

Phase 3 × Colorectal Neoplasms × Cetuximab × Clear all

NCT05239741 2026-04-17

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06662786 2026-04-13

OrigAMI-2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-04-13

OrigAMI-3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05253651 2026-04-07

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05863195 2026-03-23

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07389265 2026-02-05

CAPRI-3 GOIM

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT04776655 2025-10-02

LIBImAb

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 5 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT07004413 2025-06-04

FIRE-11

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04793958 2025-02-11

KRYSTAL-10

Phase 3 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01878422 2025-01-31

ITACa

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01167725 2024-12-27

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04687631 2024-12-18

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02563002 2024-10-03

KEYNOTE-177

Phase 3 Completed

307 enrolled 16 charts 3 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06616259 2024-09-27

CAPCET-III

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06226857 2024-01-29

CRC01

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02928224 2023-12-21

BEACON CRC

Phase 3 Completed

702 enrolled 82 charts 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT00079066 2023-08-04

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04262635 2023-08-02

C-CLASSIC

Phase 3 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05948072 2023-07-17

Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05797467 2023-05-24

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03391934 2023-04-05

Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Phase 3 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT01001377 2022-09-21

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 Completed

1,010 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00265811 2020-11-09

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

Phase 3 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04525326 2020-08-25

Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases

Phase 3 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04509635 2020-08-12

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis

Phase 3 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT00265850 2020-05-07

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Phase 3 Completed

2,334 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02484833 2020-03-31

Erbitux MEtastatic Colorectal Cancer Strategy Study

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01228734 2020-01-28

TAILOR

Phase 3 Completed

553 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT00252564 2019-02-15

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Phase 3 Completed

247 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT00077233 2018-05-16

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Phase 3 Terminated

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03362684 2017-12-05

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01309126 2017-07-13

PRIMUS

Phase 3 Terminated

Gastrointestinal

Recurrence, Colorectal Neoplasms

NCT00154102 2017-01-30

CRYSTAL

Phase 3 Completed

1,221 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT01338558 2016-11-02

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

Phase 3 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT01030042 2015-07-15

COMETS

Phase 3 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00433927 2014-03-14

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

Phase 3 Unknown

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00182715 2013-09-17

Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 3 Unknown

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00482222 2013-01-23

Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer

Phase 3 Unknown

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00208546 2012-02-02

Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00145314 2011-01-14

FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00061815 2010-04-12

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00063141 2010-04-12

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms